Guerbet: commercial launch of Elucirem in France

(CercleFinance.com) - Guerbet announces the commercial launch in France of its new Elucirem contrast agent for magnetic resonance imaging (MRI) examinations, its approval for local authorities having been published on November 19 in the Journal Officiel.


Indicated in the EU for people aged two and over, Elucirem improves the detection and visualization of pathologies associated with disruption of the blood-brain barrier and/or abnormal vascularization in several organs.

The Elucirem molecule, gadopiclenol, has been designed to meet the challenges of dose reduction and safety. Thanks to its high relaxivity and kinetic stability, it makes it possible to halve the amount of gadolinium injected into patients.

Copyright (c) 2024 CercleFinance.com. All rights reserved.